Biogen is mulling new options in its search for a CEO after talks with a senior research executive from Johnson & Johnson reached an impasse, STAT has learned.
Mathai Mammen, a well-regarded scientist and head of R&D at pharmaceutical giant J&J, had been a frontrunner to become Biogen’s next leader as late as last month. But more recently, talks between Mammen and the company’s board broke down, according to a person familiar with the situation.
One sticking point, the person said, was that Mamman wanted influence over the future makeup of Biogen’s board, which might have helped him push through strategic changes at the company. But Biogen Chairman Stelios Papadopoulos was unwilling to accept Mammen’s terms, the person said, and the two sides parted ways.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect